 |
인쇄하기
취소
|
Three antihypertensive agents get green light for clinical trails
The Korea Food and Drug Administration said that three drug makers were given the green light to conduct the clinical tests of three different antihypertensive drugs between August 29 and September 2.
1) Jeil Pharm: Phase II trials in hypertension with ACALAS (OJP-2028), a novel calcium channel antagonist, in a bid to confirm the appropriate dosage and administration;
2) GlaxoSmithKline: ...
1) Jeil Pharm: Phase II trials in hypertension with ACALAS (OJP-2028), a novel calcium channel antagonist, in a bid to confirm the appropriate dosage and administration;
2) GlaxoSmithKline: ...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.